25 related articles for article (PubMed ID: 38672614)
1. KMT9 Controls Stemness and Growth of Colorectal Cancer.
Berlin C; Cottard F; Willmann D; Urban S; Tirier SM; Marx L; Rippe K; Schmitt M; Petrocelli V; Greten FR; Fichtner-Feigl S; Kesselring R; Metzger E; Schüle R
Cancer Res; 2022 Jan; 82(2):210-220. PubMed ID: 34737213
[TBL] [Abstract][Full Text] [Related]
2. Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death.
Baumert HM; Metzger E; Fahrner M; George J; Thomas RK; Schilling O; Schüle R
Cancer Cell Int; 2020; 20():52. PubMed ID: 32095117
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of KMT9α Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer.
Koll FJ; Metzger E; Hamann J; Ramos-Triguero A; Bankov K; Köllermann J; Döring C; Chun FKH; Schüle R; Wild PJ; Reis H
Cells; 2023 Feb; 12(4):. PubMed ID: 36831256
[TBL] [Abstract][Full Text] [Related]
4. Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity.
Wang S; Klein SO; Urban S; Staudt M; Barthes NPF; Willmann D; Bacher J; Sum M; Bauer H; Peng L; Rennar GA; Gratzke C; Schüle KM; Zhang L; Einsle O; Greschik H; MacLeod C; Thomson CG; Jung M; Metzger E; Schüle R
Nat Commun; 2024 Jan; 15(1):43. PubMed ID: 38167811
[TBL] [Abstract][Full Text] [Related]
5. KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells.
Metzger E; Wang S; Urban S; Willmann D; Schmidt A; Offermann A; Allen A; Sum M; Obier N; Cottard F; Ulferts S; Preca BT; Hermann B; Maurer J; Greschik H; Hornung V; Einsle O; Perner S; Imhof A; Jung M; Schüle R
Nat Struct Mol Biol; 2019 May; 26(5):361-371. PubMed ID: 31061526
[TBL] [Abstract][Full Text] [Related]
6. Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.
Totonji S; Ramos-Triguero A; Willmann D; Sum M; Urban S; Bauer H; Rieder A; Wang S; Greschik H; Metzger E; Schüle R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672614
[TBL] [Abstract][Full Text] [Related]
7. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.
Kiselyov A; Bunimovich-Mendrazitsky S; Startsev V
Int J Cancer; 2016 Jun; 138(11):2562-9. PubMed ID: 26547270
[TBL] [Abstract][Full Text] [Related]
8. New horizons in bladder cancer research.
Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
[TBL] [Abstract][Full Text] [Related]
9. Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.
Bellmunt J
Biomedicines; 2018 Aug; 6(3):. PubMed ID: 30072631
[TBL] [Abstract][Full Text] [Related]
10. The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells.
Mierke CT
Rep Prog Phys; 2019 Jun; 82(6):064602. PubMed ID: 30947151
[TBL] [Abstract][Full Text] [Related]
11. Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review.
König F; Pradere B; Grossmann NC; Quhal F; Rajwa P; Laukhtina E; Mori K; Katayama S; Yanagisawa T; Mostafai H; Motlagh RS; Aydh A; Dahlem R; Shariat SF; Rink M
Transl Cancer Res; 2022 Apr; 11(4):908-917. PubMed ID: 35571640
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
